The idea to resume maintenance strategies appears particularly appealing in situations, such as the presence of complex or monosomic karyotype, TP53 mutations or high/very high pre-transplant MRD levels, in which GVL alone may fail to keep residual AML under control [34]. The gene discussed is TP53; the disease is acute myeloid leukemia.